SCHEMBL2875231

SCHEMBL2875231

O=C(Nc1ccccc1Cl)c1cnn2ccc(N3CCCCC3)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
EPHB3 P54753 17/20 1.00
RIPK2 O43353 1/20 0.64
LCK P06239 1/20 0.64
IRAK4 Q9NWZ3 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2877098 0.99 EPHB3 (0.98) EPHB3RIPK2LCKIRAK4
SCHEMBL2875489 0.90 EPHB3 (1.00) EPHB3RIPK2LCKIRAK4
SCHEMBL2874133 0.82 EPHB3 (1.00) EPHB3RIPK2LCK
SCHEMBL2873995 0.80 EPHB3 (1.00) EPHB3RIPK2LCK
SCHEMBL19562840 0.80 EPHB3 (0.67) EPHB3IRAK4
SCHEMBL2878098 0.79 EPHB3 (1.00) EPHB3RIPK2LCKIRAK4
SCHEMBL19562741 0.79 EPHB3 (0.65) EPHB3IRAK4
SCHEMBL19562933 0.79 EPHB3 (0.64) EPHB3IRAK4
SCHEMBL19562537 0.78 EPHB3 (0.64) EPHB3
SCHEMBL22170113 0.78 EPHB3 (1.00) EPHB3RIPK2LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010117787-A2 INHIBITING EPH B-3 KINASE THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2010-10-14 WO claimed
US-8927545-B2 Inhibiting Eph B-3 kinase DUKE UNIVERSITY (US) 2015-01-06 US disclosed
US-20120238597-A1 Inhibiting EPH B-3 Kinase DUKE UNIVERSITY (US) 2012-09-20 US disclosed
WO-2010117787-A2 INHIBITING EPH B-3 KINASE THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238597-A1 Inhibiting EPH B-3 Kinase EPHB3, EPHB1, EPHB2 EPHB3 1/4885RIPK2 173/4885LCK 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.